Assertio Holdings (ASRT) Share-based Compensation (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Share-based Compensation came in at $725000.0 in Q1 2026, down 34.15% year-on-year from $1.1 million in Q1 2025, and up 647.42% quarter-over-quarter from $97000.0 in Q4 2025.
Assertio Holdings (ASRT) Share-based Compensation (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Share-based Compensation across 8 years of filings, most recently posting $725000.0 for Q1 2026.
- Share-based Compensation for Q1 2026 came in at $725000.0, down 34.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (down 37.22% YoY), and the FY2025 annual result was $3.5 million, down 31.04% from the prior year.
- Share-based Compensation came in at $725000.0 for Q1 2026 at Assertio Holdings, up from $97000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.6 million in Q4 2023 to a low of $97000.0 in Q4 2025.
- The 5-year median for Share-based Compensation is $1.3 million (2024), against an average of $1.5 million.
- Across the five-year window, Share-based Compensation surged 176.82% in 2022 and tumbled 91.17% in 2025, its largest moves.
- Assertio Holdings' Share-based Compensation stood at $2.4 million in 2022, then gained by 10.64% to $2.6 million in 2023, then plunged by 58.44% to $1.1 million in 2024, then sank by 91.17% to $97000.0 in 2025, then surged by 647.42% to $725000.0 in 2026.
- The last three Share-based Compensation figures came in at $725000.0 (Q1 2026), $97000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 43.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 25.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 33.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -395,114.54 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 57.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 21.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 36.33 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 36.86 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 16.04 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | 725,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 725,000.00 |
| Mar 31, 2026 | 725,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | 2.64 Mn |
| Dec 31, 2023 | 2.64 Mn |